CTXR Stock Overview
A biopharmaceutical company, focuses on the development and commercialization of critical care products. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Citius Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.67 |
| 52 Week High | US$26.75 |
| 52 Week Low | US$2.44 |
| Beta | 1.29 |
| 1 Month Change | -28.03% |
| 3 Month Change | -74.05% |
| 1 Year Change | -83.77% |
| 3 Year Change | -92.93% |
| 5 Year Change | -90.29% |
| Change since IPO | -99.29% |
Recent News & Updates
Recent updates
We Think Citius Pharmaceuticals (NASDAQ:CTXR) Needs To Drive Business Growth Carefully
Apr 06
We're Keeping An Eye On Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Rate
Dec 08Will Citius Pharmaceuticals (NASDAQ:CTXR) Spend Its Cash Wisely?
Aug 01We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth
Apr 12Here's Why We're Watching Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Situation
Dec 25Citius Pharma submits biologics license application to FDA for immunotherapy I/ONTAK
Sep 28Citius Pharmaceuticals GAAP EPS of -$0.06
Aug 11Here's Why Citius Pharmaceuticals (NASDAQ:CTXR) Must Use Its Cash Wisely
Aug 05Citius holds pre-biologics license application meeting with FDA for immunotherapy I/ONTAK
Jul 12Citius Pharmaceuticals: Hoping For A Turnaround Strategy
Jul 05Critical Care Biopharma - Citius Pharmaceuticals
Apr 13Citius: 2022 Is A Year Of Catalysts
Mar 28We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth
Dec 04Citius Pharmaceuticals, Inc.: Burning Cash Before Commercialization
Sep 26Companies Like Citius Pharmaceuticals (NASDAQ:CTXR) Are In A Position To Invest In Growth
Aug 28Citius: Halt For Superiority On The Horizon
Jun 15We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth
May 15Citius Pharmaceuticals shares rise in anticipation of Mino-Lok phase 3 results
Apr 26Is Citius Pharmaceuticals (NASDAQ:CTXR) In A Good Position To Deliver On Growth Plans?
Dec 18Shareholder Returns
| CTXR | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -0.7% | 0.2% | 0.2% |
| 1Y | -83.8% | 1.3% | 22.0% |
Return vs Industry: CTXR underperformed the US Pharmaceuticals industry which returned 1.3% over the past year.
Return vs Market: CTXR underperformed the US Market which returned 22% over the past year.
Price Volatility
| CTXR volatility | |
|---|---|
| CTXR Average Weekly Movement | 21.2% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 18.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CTXR's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CTXR's weekly volatility has increased from 15% to 21% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 23 | Leonard Mazur | citiuspharma.com |
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company’s late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.
Citius Pharmaceuticals, Inc. Fundamentals Summary
| CTXR fundamental statistics | |
|---|---|
| Market cap | US$22.77m |
| Earnings (TTM) | -US$40.19m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.6x
P/E RatioIs CTXR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CTXR income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$40.19m |
| Earnings | -US$40.19m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.68 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CTXR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/07 23:06 |
| End of Day Share Price | 2025/02/07 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Citius Pharmaceuticals, Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Kolbert | D. Boral Capital LLC. |
| Jason Kolbert | H.C. Wainwright & Co. |
| Vernon Bernardino | H.C. Wainwright & Co. |